从微小RNAs看肝细胞癌诊治新视点

李强; 卓其斌; 黄玉仙; 陈良

doi:10.3969/j.issn.1001-5256.2015.06.037

从微小RNAs看肝细胞癌诊治新视点

DOI: 10.3969/j.issn.1001-5256.2015.06.037

复旦大学附属公共卫生临床中心肝炎一科

基金项目:

2013-2014年度国家临床重点专科建设项目-感染病科；上海市科委“科技创新行动计划”医学与农业领域重点项目(13401902100)；上海市卫生局临床医学应用研究项目(20114279)；

详细信息

中图分类号: R735.7
计量
- 文章访问数: 1906
- HTML全文浏览量: 18
- PDF下载量: 496
- 被引次数: 0
出版历程
- 出版日期: 2015-06-20

Diagnosis and treatment of hepatocellular carcinoma from a new perspective of miRNAs

Research funding:

摘要

摘要: 利用当前血清生物标志物诊断的肝细胞癌(HCC)通常已处于晚期阶段;在目前现有治疗方案下,HCC的5年生存率很低。因此,有必要研发高效、无创、能早期诊断HCC的生物标志物,探索治疗HCC的新策略。很多证据表明微小RNAs(miRNAs)参与HCC发生发展过程,有可能成为检测HCC癌变的敏感生物学标志物和治疗HCC的新靶标。介绍了miRNAs在HCC诊治中的应用,认为以miRNAs为基础的HCC诊治策略在临床上具有很好的应用前景,但尚需进一步深入的研究。
- 癌,肝细胞 /
- 微RNAs /
- 早期诊断 /
- 治疗 /
- 综述
Abstract: The hepatocellular carcinoma( HCC) diagnosed by serum biomarkers is usually at late stages,and the five- year survival rate of HCC is extremely low. Therefore,it is necessary to develop an efficient and noninvasive biomarker that can detect HCC at an early stage and to explore a new strategy for the treatment of HCC. Abundant evidence has shown that microRNAs( miRNA) s is involved in the development and progression of HCC,and it can be a sensitive biomarker for the detection of HCC and a new target for the treatment of HCC. The article introduces the application of miRNAs in the diagnosis and treatment of HCC,and believes that the diagnosis and treatment strategy for HCC based on miRNAs has great potential in clinical application,yet remains to be studied.
- carcinoma,hepatocellular /
- microRNAs /
- early diagnosis /
- treatment /
- review

HTML全文

参考文献(29)

[1]LAFARP KJ,DEMIRJIAN AN,PAWLIK TM.Epidemiology of hepatocellular carcinoma[J].Surg Oncol Clin N Am,2015,24(1):1-17.

[2]SIEGEL RL,MILLER KD,JEMAL A.Cancer statistics,2015[J].CA Cancer J Clin,2015,65(1):5-29.

[3]POZZAN C,CARDIN R,PICIOCCHI M,et al.Diagnostic and prognostic role of SCCA-Ig M serum levels in hepatocellular carcinoma(HCC)[J].J Gastroenterol Hepatol,2014,29(8):1637-1644.

[4]FOMER A,DIAZ-GONZALEZ A,LICCIONI A,et al.Prognosis prediction and staging[J].Best Pract Res Clin Gastroenterol,2014,28(5):855-865.

[5]MA DQ,CUI H.Research advances in miRNA transfection in vivo[J].J Clin Exp Med,2014,13(21):1825-1829.(in Chinese)马东青,崔红.miRNA体内转染的研究进展[J].临床和实验医学杂志,2014,13(21):1825-1829.

[6]HA M,KIM VN.Regulation of microRNA biogenesis[J].Nat Rev Mol Cell Biol,2014,15(8):509-524.

[7]POGRIBNY IP,RUSYN I.Role of epigenetic aberrations in the development and progression of human hepatocellular carcinoma[J].Cancer Lett,2014,342(2):223-230.

[8]YANG N,EKANEM NR,SAKYI CA,et al.Hepatocellular carcinoma and microRNA:new perspectives on therapeutics and diagnostics[J].Adv Drug Deliv Rev,2015,81C:62-74.

[9]ZHU Z,ZHANG X,WANG G,et al.Role of microRNAs in hepatocellular carcinoma[J].Hepat Mon,2014,14(8):e18672.

[10]CALLEGARI E,GRAMANTIERI L,DOMENICALI M,et al.MicroRNAs in liver cancer:a model for investigating pathogenesis and novel therapeutic approaches[J].Cell Death Differ,2015,22(1):46-57.

[11]BERTINO G,NERI S,BRUNO CM,et al.Diagnostic and prognostic value of alpha-fetoprotein,des-gamma-carboxy prothrombin and squamous cell carcinoma antigen immunoglobulin M complexes in hepatocellular carcinoma[J].Minerva Med,2011,102(5):363-371.

[12]FONG ZV,TANABE KK.The clinical management of hepatocellular carcinoma in the United States,Europe,and Asia:a comprehensive and evidence-based comparison and review[J].Cancer,2014,120(18):2824-2838.

[13]QU KZ,ZHANG K,LI H,et al.Circulating microRNAs as biomarkers for hepatocellular carcinoma[J].J Clin Gastroenterol,2011,45(4):355-360.

[14]GIRARY BG,EMEKDAS G,TEZCAN S,et al.Profiles of serum microRNAs;miR-125b-5p and miR223-3p serve as novel biomarkers for HBV-positive hepatocellular carcinoma[J].Mol Biol Rep,2014,41(7):4513-4519.

[15]CARDIN R,PICIOCCHI M,SINIGAGLIA A,et al.Oxidative DNA damage correlates with cell immortalization and mir-92 expression in hepatocellular carcinoma[J].BMC Cancer,2012,12:177.

[16]YAMAMOTO Y,KOSAKA N,TANAKA M,et al.MicroRNA-500 as a potential diagnostic marker for hepatocellular carcinoma[J].Biomarkers,2009,14(7):529-538.

[17]BARSHACK I,MEIRI E,ROSENWALD S,et al.Differential diagnosis of hepatocellular carcinoma from metastatic tumors in the liver using microRNA expression[J].Int J Biochem Cell Biol,2010,42(8):1355-1362.

[18]WONG CC,WONG CM,TUNG EK,et al.The microRNA miR-139 suppresses metastasis and progression of hepatocellular carcinoma by down-regulating Rho-kinase 2[J].Gastroenterology,2011,140(1):322-331.

[19]AUGELLO C,VAIRA V,CARUSO L,et al.MicroRNA profiling of hepatocarcinogenesis identifies C19MC cluster as a novel prognostic biomarker in hepatocellular carcinoma[J].Liver Int,2012,32(5):772-782.

[20]YAO M,WANG L,QIU L,et al.Encouraging microRNA-based therapeutic strategies for hepatocellular carcinoma[J].Anticancer Agents Med Chem,2014.[Epub ahead of print]

[21]CHEN JJ,TANG YS,HUANG SF,et al.HBx protein-induced upregulation of microRNA-221 promotes aberrant proliferation in HBV related hepatocellular carcinoma by targeting estrogen receptor-alpha[J].Oncol Rep,2015,33(2):792-798.

[22]PARK JK,KOGURE T,NUOVO GJ,et al.MiR-221 silencing blocks hepatocellular carcinoma and promotes survival[J].Cancer Res,2011,71(24):7608-7616.

[23]CALLEGARI E,ELAMIN BK,GIANNONE F,et al.Liver tumorigenicity promoted by microRNA-221 in a mouse transgenic model[J].Hepatology,2012,56(3):1025-1033.

[24]GREENHILL C.Hepatocellular carcinoma:new insight into angiogenesis in hepatocellular carcinoma:involvement of microRNA-26a[J].Nat Rev Gastroenterol Hepatol,2014,11(1):3.

[25]NAKAO K,MIYAAKI H,ICHIKAWA T.Antitumor function of microRNA-122 against hepatocellular carcinoma[J].J Gastroenterol,2014,49(4):589-593.

[26]LU Y,YUE X,CUI Y,et al.MicroRNA-124 suppresses growth of human hepatocellular carcinoma by targeting STAT3[J].Biochem Biophys Res Commun,2013,441(4):873-879.

[27]BOUCHIE A.First microRNA mimic enters clinic[J].Nat Biotechnol,2013,31(7):577.

[28]LI X,YANG W,LOU L,et al.MicroRNA:a promising diagnostic biomarker and therapeutic target for hepatocellular carcinoma[J].Dig Dis Sci,2014,59(6):1099-1107.

[29]HSU SH,YU B,WANG X,et al.Cationic lipid nanoparticles for therapeutic delivery of siRNA and miRNA to murine liver tumor[J].Nanomedicine,2013,9(8):1169-1180.

施引文献

资源附件(0)

访问统计